Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06174753 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dapagliflozin in STEMI

Study acronym: DAPA STEMI
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 2026 to Jun 2027
    • Study completion date: Sep 2026 to Dec 2027
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2025 to Jan 20, 2025
    • Site details revised
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Primary completion date: Feb 2025 to Feb 2026v2 Show 5 more changesShow less
    • Start date: Feb 2024 to Feb 2025
    • Study completion date: Sep 2025 to Sep 2026
    • Eligibility criteria shortened, about 33 words
    • Secondary endpoints revised (3)
    • Study title shortened, about 3 words
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Trial Details
NCT Number NCT06174753
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions
(from sponsor)		 ST Elevation Myocardial Infarction, Myocardial Infarction
Related terms Myocardial Infarction, ST Elevation Myocardial Infarction
Enrollment 256 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov